StockData

Rafael Holdings, Inc. (RFL) company profile

RFLNYSEPharmaceutical PreparationsFiscal year ends July 31
Số liệu tài chính tới Q4 năm tài chính 2026, quý kết thúc ngày Jul 31, 2026Last filing: 10-K on Oct 29, 2026Score 5/30
$0.91−0.06 (-5.84%)

Close on Nov 17, 2026Market cap $47.67MP/E –Yield –

About Rafael

Pharmaceutical Preparations, SIC 2834

Rafael Holdings, Inc. is a biotechnology company that develops pharmaceuticals and holds interests in early-stage and clinical healthcare and technology businesses. Its lead drug candidate, Trappsol Cyclo (remibetadex), targets Niemann-Pick Disease Type C. Through its subsidiaries and majority-owned portfolio entities, the company engages in liposomal cancer therapies via LipoMedix, orthopedic surgical instruments through Rafael Medical Devices, and product formulation technologies via Day Three Labs. It also retains legacy interests in cancer therapeutics and commercial real estate. Customers and commercial end users include healthcare providers, surgical specialists, diagnostic and pharmaceutical companies purchasing cyclodextrins, and third-party manufacturers utilizing proprietary ingredient technology.

The company's clinical research spans global clinical trial operations, having authorized Phase 3 study sites across 13 countries including the United States, United Kingdom, Israel, Germany, and Brazil. Rafael Holdings is headquartered in Newark, New Jersey, and retains an interest in a commercial building in Jerusalem, Israel.

Summary of the business section of Rafael's latest annual report, written by StockData.

Company profile

Company

Legal name
Rafael Holdings, Inc.
Headquarters
Newark, NJ
Address
520 Broad Street 07120
Phone
(212) 658-1450
Employees
17, Jul 31, 2026
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
July 31
Auditor
CohnReznick LLP, Hartford, Connecticut

Stock & identifiers

Ticker
RFL
Exchange
NYSE
Shares outstanding
52M, Oct 26, 2026
Public float
$37.20M, Jan 30, 2026
Filer category
Non-accelerated filer<br>Smaller reporting company
SEC CIK
1713863
CUSIP
75062E106
ISIN
US75062E1064
FIGI
BBG00J3YYS92
Share class FIGI
BBG00J3YYSB9
EIN
82-2296593

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Howard S. JonasExec Chairman, CEO & President, Director15,042,008
David PolinskyChief Financial Officer292,839
Joshua M. FineChief Operating Officer9,380
William ConklingChief Executive Officer564,455
John GoldbergCHIEF MEDICAL OFFICER50,000
Markus SiegerDirector219,710
Mark N. SteinDirector50,845
Michael J. WeissDirector141,861
Alan GraysonDirector6,562
N. Scott FineDirector335,348
Stephen M. GreenbergDirector102,491

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025
Howard Jonas
$294.00K$298.89K$530.55K$85–
FY2025
William Conkling
$592.91K$611.63K$530.55K$85–
FY2024$859.30K$658.22K$649.20K$74–
FY2023$751.95K$685.32K$406.69K$99–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOtherTotalvs. prior year
Howard Jonas
Chairman of the Board, Chief Executive Officer (3) and Executive Chairman
$44.00K–$250.00K–$294.00K-46%
William Conkling
Chief Executive Officer (6)
$447.61K–$117.24K$28.07K$592.91K-31%
John Goldberg
Chief Medical Officer (11)
$427.30K–$97.70K$8.75K$533.75K-30%
David Polinsky
Chief Financial Officer (16)
$300.01K$120.00K$97.70K$9.64K$527.35K–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“ur different businesses units is critical to our success . As of October 15, 2026, Rafael Holdings and its subsidiaries had 15 full-time and 2 part-time employees. Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and i”

Corporate history

Events identified from SEC filings

See a number that looks wrong?